Integral Health Asset Management’s Denali Therapeutics DNLI Stock Holding History

Integral Health Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.57M	Buy	+100,000	New	+$2.05M	0.1%	89
2024 Q3	–	Sell	-325,000	Closed	-$7.55M	–	72
2024 Q2	$7.55M	Buy	+325,000	New	+$6.24M	0.72%	45
2022 Q4	–	Sell	-115,000	Closed	-$3.53M	–	74
2022 Q3	$3.53M	Buy	+115,000	New	+$3.74M	0.69%	49
2022 Q2	–	Sell	-26,000	Closed	-$836K	–	71
2022 Q1	$836K	Sell	26,000 -74,000	-74%	-$2.55M	0.22%	67
2021 Q4	$4.46M	Buy	100,000 +25,000	+33%	+$1.18M	1.23%	30
2021 Q3	$3.78M	Sell	75,000 -6,000	-7%	-$338K	1.09%	36
2021 Q2	$6.35M	Sell	81,000 -16,000	-16%	-$990K	1.75%	22
2021 Q1	$5.54M	Buy	97,000 +39,500	+69%	+$2.64M	1.58%	25
2020 Q4	$4.82M	Sell	57,500 -107,500	-65%	-$6.5M	1.43%	27
2020 Q3	$5.91M	Buy	165,000 +35,000	+27%	+$1.05M	1.81%	19
2020 Q2	$3.14M	Buy	130,000 +40,000	+44%	+$940K	0.94%	43
2020 Q1	$1.58M	Buy	+90,000	New	+$1.88M	0.69%	44

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Integral Health Asset Management's DNLI Position: Q2 2026 in Review

Integral Health Asset Management opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 100,000 shares worth $2.57M. The stake represents 0.1% of the portfolio and ranks #89 among its holdings. This is a return to the name: Integral Health Asset Management previously reported a position in DNLI as recently as Q2 2024.

Integral Health Asset Management first reported a position in DNLI in Q1 2020 and has held it in 12 quarters since. The position peaked at $7.55M in Q2 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Integral Health Asset Management held 100,000 shares of Denali Therapeutics worth $2.57M as of Q2 2026.
Denali Therapeutics was a new Integral Health Asset Management position in Q2 2026.
Denali Therapeutics made up 0.1% of Integral Health Asset Management's portfolio in Q2 2026, its #89 holding.
Integral Health Asset Management first reported a position in Denali Therapeutics in Q1 2020 and has held it in 12 quarters since.
Integral Health Asset Management's Denali Therapeutics position peaked at $7.55M in Q2 2024.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.